H.E.L Group Appoints Rajeev Kumria as General Manager of H.E.L India
H.E.L Group (H.E.L), a global developer and manufacturer of innovative laboratory tools for process optimization, safety, and scale-up, today announced the appointment of Rajeev Kumria as General Manager of H.E.L India. This announcement follows the recent news that H.E.L is expanding operations in India by moving to a wholly-owned subsidiary in the country. Rajeev will oversee the creation and commercial effectiveness of this new business.
Rajeev brings twenty-five years of experience in general management, M&A, business development, strategy, sales leadership, and product consultancy across medical device and diagnostics sectors. He has extensive experience of managing businesses in South Asia holding leadership roles in companies such as Getinge Medical India, Thermo Fisher Scientific, Transasia Biomedical, and Bharat Serums and Vaccines Ltd. Rajeev has managed acquisitions in both the USA and Europe as well as being involved in incubating and guiding start-ups in the field of Genetics and Mechanical Ventilation throughout his career. Rajeev has been active in the fight against the pandemic by advising companies in India developing RTPCR, nucleic acid extraction, and viral transport media products for COVID-19.
As well as setting up the new H.E.L entity, Rajeev will work closely with H.E.L’s existing commercial partners, Skytech Systems, to ensure a smooth handover of business, focusing on the continuity of customer support.
Louise Madden, CEO of H.E.L Group, commented: “We’re delighted to have Rajeev joining H.E.L at this exciting time. We have a great history with customers in India, and setting up our own entity in the country will see even greater successes. With a leader like Rajeev heading up the team, we have a fantastic mix of both General Management and commercial leadership to draw on, and I’m convinced that Rajeev and the team will support our customers and help them achieve their full potential.”
Rajeev Kumria, General Manager, H.E.L India, added: “India is a hugely dynamic market across many sectors of technology development, from fine chemicals, through battery development and testing, to the biotechnology area. H.E.L Group has great capabilities in these areas, and I’m delighted to be joining the team and leading the next stage in the growth of H.E.L in India.”
From 1 February 2022, sales, service, and support inquiries should be directed to H.E.L India – email@example.com, firstname.lastname@example.org, or via https://helgroup.com/contact/
People In This Post
Companies In This Post
- Bayer Expands Global Clinical Program for NUBEQA® (darolutamide) in Prostate Cancer Read more
- BIOTECanada Welcomes Government of Canada’s Strategy on Improving Access to Care for Patients with Rare Diseases Read more
- Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone in the Treatment of Lennox-Gastaut Syndrome Read more
- Aurion Biotech Receives Approval from Japan’s PMDA for New Drug Application Read more
- Morphimmune Appoints Dr. Clay Siegall Chief Executive Officer and President Read more